The CASSS Cell & Gene Therapy Products (CGTP) Symposium, held from June 11-13 in Rockville, Maryland, was an exceptional gathering for professionals dedicated to advanced therapies. The exchange of knowledge and expertise, coupled with the shared advancements in good science and CMC, significantly propelled the industry forward.
Dr. Jing Fan, the founder and CEO of Hopstem, delivered an informative presentation on "Stem Cell-derived Medicinal Products" Plenary Session, with a focus on "Development of Releasing Criteria and Potency Assays for an iPSC-Derived Neural Progenitor Cell Product Targeting CNS Diseases." During the panel discussion, Dr. Fan and other panelists, including Kevin Okimura from Orca Bio, Andreea Barbu from the Swedish Medical Products Agency, Saravanan Karumbayaram from CBER, FDA, and Todd McDevitt, Head of Cell Therapy at Genentech, shared their views on interesting questions raised by the Chair or the audience.

To learn more about the session and symposium, please check out:
https://virtual.oxfordabstracts.com/#/event/5244/program

Hopstem Announces FDA Granted iPSC Therapy hNPC01 Injection Fast Track Designation, Accelerating Global Breakthrough in Treatment of Cerebral Neural Injury Diseases

Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke

Hopstem Biotechnology at 2024 CASSS CGPT Symposium

Hopstem Biotechnology to Participate in the 2024 BIO International Convention in San Diego
